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Abstract
Objective: The aim of this study was to examine the relative contributions of
body mass index (BMI) and pubertal measures for risk and age of onset of
pediatric MS. Methods: Case–control study of 254 (63% female) MS cases (onset<18 years of age) and 420 (49% female) controls conducted at 14 U.S. Pediatric MS Centers. Sex- and age-stratified BMI percentiles were calculated using
CDC growth charts from height and weight measured at enrollment for controls, and within 1 year of onset for MS cases. Sex-stratified associations
between MS risk and age at symptom onset with both BMI and pubertal factors
were estimated controlling for race and ethnicity. Results: Only 11% of girls
and 15% of boys were prepubertal (Tanner stage I) at MS onset. 80% of girls
had onset of MS after menarche. BMI percentiles were higher in MS cases
versus controls (girls: P < 0.001; boys: P = 0.018). BMI was associated with
odds of MS in multivariate models in postpubertal girls (OR = 1.60, 95%
confidence interval [CI]: 1.12, 2.27, P = 0.009) and boys (OR = 1.43, 95% CI:
1.08, 1.88, P = 0.011). In girls with MS onset after menarche, higher BMI was
associated with younger age at first symptoms (P = 0.031). Younger menarche
was associated with stronger effects of BMI through mediation and interaction
analysis. In pubertal/postpubertal boys, 89% of whom were obese/overweight,
earlier sexual maturity was associated with earlier onset of MS (P < 0.001).
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Interpretation: Higher BMI in early adolescence is a risk factor for MS in
girls and boys. Earlier age at sexual maturity contributes to earlier age at MS
onset, particularly in association with obesity.

Introduction
Several lines of evidence suggest that puberty and elevated
body mass index (BMI) may contribute to the risk of
MS. An elevated female:male sex ratio in pediatric MS
appears with onset around the age of 11,1 suggesting a
role for puberty as a turning point for the initiation of
MS. Earlier menarche (onset of menses) has been
observed in women with adult-onset MS compared to
healthy females,2 suggesting that hormonal changes at
puberty may influence early MS pathogenetic mechanisms. There is increasing evidence suggesting that the
peri-pubertal period is critical period for exposure to
environmental risk factors for MS, such as exposure to
EBV/infectious mononucleosis, place of residence, sunlight exposure, and hypovitaminosis D (reviewed3).
Prior studies have suggested that attainment of menarche increases the risk of MS in girls with acute demyelinating syndrome (ADS),4 and that relapse rate increases
in girls in the peri-menarcheal phase.5 One study has
demonstrated a marginally earlier age at menarche in a
large cohort of females with MS.2 A study in adult MS
revealed a slight but significant difference in age at
menarche in MS patients versus healthy individuals
(12.4 vs. 12.6 years, P < 0.001). The relative risk reduction was 0.9 per each year of increased age at menarche.
Another study reported similar findings: with each oneyear increase in the age at menarche, the age at first
symptoms was postponed by 1.16 years.6
In parallel, there is increasing evidence that obesity
during adolescence is associated with a higher risk of MS
in adults.7–11 In children, one study found an effect of
obesity in girls but not in boys;12 however, a smaller
number of male cases may have limited the ability to
detect an effect. A higher BMI during adolescence may be
associated with younger age at MS onset in women.13
Attainment of sufficient body weight, and particularly
body fat, is believed to be necessary for menarche to
occur in girls,14,15,3,16 and higher body weight is associated with earlier pubertal onset in girls.
Puberty and obesity hormonal pathways impact the
immune system, with potentially differing effects on MS
triggers.17–19 Thus, there is need to further clarify the
specific effects of sex hormones and obesity-related factors
on the risk and age of MS onset. Pediatric MS is an ideal
setting to answer these questions, since symptoms appear
close to puberty allowing for better recall and measurement of pubertal milestones.
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In this study, we explored the effects of menarcheal
age, pubertal staging and BMI on risk of MS and age of
onset in a multicenter U.S. cohort of children with or
without MS recruited from the same centers.

Methods
Study setting
This case–control study was carried out as part of a larger
investigation on pediatric MS risk factors conducted at 14
pediatric MS centers (R01NS071463, PI Waubant). Participating centers: Ann & Robert H. Lurie Children’s Hospital of Chicago, Boston Children’s Hospital, Children’s
Hospital of Colorado, Children’s Hospital of Philadelphia,
Loma Linda University, Massachusetts General Hospital
for Children, Mayo Clinic Rochester, State University of
New York at Buffalo, Stony Brook University Medical
Center, Texas Children’s Hospital Baylor, University of
Texas Southwestern/Children’s Medical Center Dallas,
University of Alabama, University of California San Francisco, and Washington University School of Medicine in
St. Louis. Participants were recruited between November
2011 and June 2014. This study was approved by the
institutional review board at each participating institution, and consent was obtained as per individual institutional guidelines.
Clinical data were prospectively collected from pediatric
MS patients using standardized case report forms, including demographic features, developmental history, medical
history information, and neurological examinations at visits.20 Data were entered into an OpenClinica database,
housed at the University of Utah, Data Coordinating and
Analysis Center.

Study participants
Cases included children with a diagnosis of relapsingremitting MS (RRMS) with onset before 18 years of age
and less than 4 years of disease duration.17 Eligibility of
all cases was ascertained by a review committee (LK, TL,
EW). Eligibility for controls included age less than
22 years, absence of autoimmune disorders (except for
asthma or eczema), past treatment with immunosuppressive therapy, and severe health conditions. Parents of
controls could not have MS. Eligible controls were
invited to participate by recruitment in general or specialty pediatric clinics at the same participating
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institutions. Controls were selected in order to have similar distributions of sex, age, and race/ethnicity as cases in
a larger study. Race and ethnicity were self-reported
according to NIH categories.
BMI measurements: We used the 2000 CDC Growth
Charts (http://www.cdc.gov/growthcharts/cdc_charts.htm)
to calculate BMI z-scores (number of standard deviations
from average) and BMI percentiles as well as height and
weight-for-age z-scores and percentiles. We considered
children overweight or obese if their BMI was above the
85th or 95th percentiles for age, respectively. BMI for MS
cases was calculated using heights and weights recorded
within 1 year of disease onset. Measurements for controls
were taken at the enrollment visit. Children with missing
height, weight, or age values were excluded from these analyses, as were implausible values (BMI z-score beyond 4).
Sexual maturity measurements: Puberty is characterized by thelarche (breast development) and pubarche
(onset of pubic hair) followed by menarche in girls; and
by gonadarche (enlargement of testicles) and pubarche
in boys. These transitions follow characteristic changes
in the hypothalamic-pituitary-gonadal axis including
increasing pulsatile secretion of the gonadotropins and
production of sex hormones by the gonads. Adrenal
maturation (adrenarche), which is associated with
increasing levels of the adrenal hormones, precedes gonadarche by a couple of years. Sexual maturity was
assessed using Tanner staging21,22 at the first clinic visit
following initial symptoms for MS cases, and at the
enrollment visit for controls.
Tanner staging: Tanner staging describes breast development in girls, genital development in boys, and pubic hair
in both, and ranges from prepubertal (Tanner stage I) to
fully mature (Tanner stage V). Tanner staging for pubic
hair (2) is as follows: Stage I: no hairs; Stage II: sparse,
lightly pigmented hairs along the labia majora in girls and
at the base of the phallus in boys; Stage III: increasing hairs
that are more pigmented and beginning to curl spreading
to the mons; Stage IV: pigmented coarser hairs that cover
the mons but have not spread to the medial thighs; Stage
V: spread of pubic hairs to the medial thighs. Tanner staging was obtained by showing parents and child (if adolescent) Tanner staging pictures (1 and 2), and asking them
to circle the most appropriate match. Because Tanner stage
2 (hair growth) has been shown to demonstrate high interrater reliability,23 we used this as our primary marker of
sexual maturity in boys. Additionally, we categorized boys
as having advanced maturity for their age when the child’s
age was more than one standard deviation below the average age of controls with the same Tanner stage 2 (for pubic
hair). Boys whose age was above that threshold, and all
boys at Tanner stage I, were considered as not having
advanced maturity.

Puberty and Obesity effects on risk and age at pediatric MS

We stratified analyses of girls by menarcheal status.
Girls, who had experienced menarche at or before the age
of onset of first MS symptoms, were considered postmenarcheal for our analyses. We excluded girls for whom
data on menarche was not documented (17% of cases,
6% of controls) or for whom age at menarche was not
documented (2% of postpubertal cases, 3% of postpubertal controls). Pubertal boys were defined as those who
had reached at least Tanner stage II for pubic hair at the
clinic visit following first symptoms. We excluded boys
who did not have Tanner stage documented within a year
of first symptoms in cases (about 34%) or at enrollment
in controls (12%).

Statistical analysis
We compared pediatric onset MS cases to concurrently
enrolled non-MS controls for demographics, pubertal
characteristics, height, weight, and BMI using frequencies,
percentages and means and standard deviations (SD). We
tested for differences between cases and controls using
Fisher’s exact tests for discrete characteristics, and Wilcoxon rank-sum tests for continuous characteristics. We
also tested for differences among boys and girls separately.
We tested for a difference in age at menarche between
cases and controls, adjusting for race and ethnicity, using
a Van Elteren’s test.
Among MS cases, the association between being overweight or obese and prepubertal onset was tested with
Fisher’s exact tests for boys and girls separately. Associations between age at menarche and BMI in female cases
and controls were estimated using Spearman correlation
coefficients (q). The association between being overweight
or obese and having advanced maturity in male cases and
controls was tested using the Fisher’s exact test.
We compared age at menarche (females), and the percent of MS cases who were overweight or obese using
estimates obtained from children enrolled in the 2011–
2012 National Health and Nutrition Examination Survey
(NHANES) (http://www.cdc.gov/nchs/nhanes.htm). We
compared cases to NHANES estimates by age and gender, race and ethnicity. Confidence intervals and P values for differences were calculated by combining
standard error estimates from the two data sources.
We used logistic regression models to estimate associations between obesity, puberty, and the risk of MS adjusting for race/ethnicity. We modeled pre and
postmenarcheal onset girls, pre and pubertal/postpubertal
boys separately, and estimated both unadjusted and
adjusted ORs from logistic regression models, with 95%
confidence intervals (CIs) and P-values testing for associations. Model fit was evaluated using Hosmer and Lemeshow goodness of fit tests.
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Linear regression models were used to estimate associations between obesity, puberty, race/ethnicity, and age of
symptom onset among MS patients. We modeled pre and
postmenarcheal girls, and pre and pubertal/postpubertal
boys separately. We estimated unadjusted and adjusted
regression coefficients with 95% CIs and P-values testing
for linear associations.

Compared to NHANES controls, MS girls aged
12–16 years old were more likely to be overweight or
obese (P < 0.001) (Table S1) but differences were less
conclusive in other age groups and among males. Overall,
there were relatively more overweight/obese MS children
in all age and gender categories, although only some comparisons reached statistical significance (Table S1b).

Mediation analysis

Puberty markers

Due to the relationship between obesity and puberty
among postmenarcheal girls, we utilized methods explained
by VanderWeele24,25 to estimate the mediating and interacting effects of menarcheal age, and the effect of BMI, on
both the risk of MS, and the age at onset of MS. These
models assume that BMI affects menarche and the outcome
(either risk of MS or age at onset); menarche affects the
outcome; the outcome affects neither predictor; and
menarche does not affect BMI. This method also assumes
that confounders are sufficiently controlled (these models
control for race and ethnicity) and requires assumptions
about consistency and composition, which assumptions are
discussed elsewhere.24 Models result in estimates of the
total combined effect of BMI and menarcheal age on the
outcome. That effect is also decomposed into four components including a controlled direct effect of BMI (due neither to mediation or interaction), a reference interaction
effect (due to interaction only), a mediated interaction
effect (due to mediation and interaction), and a pure indirect effect (due to mediation of menarcheal age alone).

Females

Results

Among female MS cases, 89% of girls were Tanner
stage II or higher for pubic hair during the year of
first symptom onset (Table 1, Fig. 2B). Among female
MS cases, 80% had experienced menarche by the year
of disease onset. Age at menarche was marginally
younger in MS cases compared to controls (11.6 vs.
11.9 years, Wilcoxon rank-sum P = 0.025). However,
after adjusting for race/ethnicity, there was less evidence
of an association (P = 0.056). Compared to NHANES
controls, pediatric-onset MS cases were significantly
younger at menarche overall, (mean age 11.6 vs.
12.7 years, P < 0.001), and when stratified by race/ethnicity groups (Table S1).
Males
85% of male MS cases reported Tanner stage II or higher
for pubic hair compared to 80% of controls (P = 0.118).
(Table 1).

Puberty and obesity correlations

Participant characteristics

Females

We report on 254 MS cases and 420 controls (Table 1
Table S4). There were more female cases (63%) compared
to controls (49%) (P < 0.001). Race and ethnicity differed
between cases and controls (P = 0.004) with more Whites
in the control group.

Among MS cases, 26% of premenarcheal females were
overweight or obese compared to 60% of postmenarcheal
females (Fisher’s exact test P = 0.011 and Figure S2).
Higher BMI in cases and controls was correlated with
younger age at menarche (Spearman’s q: cases 0.26
P = 0.011, controls 0.37 P < 0.001).

BMI in MS compared to controls
BMI percentiles and z-scores were higher in girls
(P < 0.001) and boys (P = 0.018) with MS compared to
controls (Table 1 and Fig. 1A and B and Figure S1). Height
did not differ in MS cases stratified by sex versus controls.
However, weight percentiles and z-scores were higher in
female cases versus controls (P < 0.001) but not in male
case versus controls. The proportion of overweight or obese
was higher in MS cases in girls (54% of cases, 33% of controls, P < 0.001) and boys (48% of cases, 34% of controls,
P = 0.057).
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Males
Among males, there was no correlation between Tanner
stage and age-adjusted BMI (Spearman’s q: cases 0.00,
P = 0.996; controls 0.01, P = 0.934).
We observed that 15% (9 of 61) of male MS cases had
advanced maturity for their Tanner staging for pubic hair
(i.e., more than 1 standard deviation younger than the
average control enrolled with the same Tanner stage). Eight
of these nine (89%) boys were overweight or obese compared to less than half (42%) of the other 52 male MS cases
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Table 1. Demographic characteristics of girls and boys with MS versus non-MS controls. Means and standard deviations given unless otherwise
noted.
Overall

Female N(%)
Race/Ethnicity N(%)
White/non-HL
Hispanic-Latino
Black/non-HL
Other race/non-HL
Unknown
Age4
Postmenarcheal (girls) or
postpubertal MS (boys)
onset N(%)6
Age at Menarche6
First Available EDSS6
Tanner Stage 1 N(%)3, 6
I
II
III
IV
V
Tanner Stage 2 N(%)3, 6
I
II
III
IV
V
BMI-for-age percentile6
BMI-for-age Z-score6
Height-for-age percentile6
Height-for-age Z-score6
Weight-for-age percentile6
Weight-for-age Z-score6
Overweight or obese5, 6

Boys

Control
N = 420

Case
N = 254

207 (49%)

161 (63%)

219 (52%)
72 (17%)
65 (15%)
40 (10%)
24 (6%)
14 (3.7)
N/A

N/A
N/A

110
74
36
21
13
14
159

(43%)
(29%)
(14%)
(8%)
(5%)
(3.4)
(82%)

Girls

Control
N = 213

P

Case
N = 93

<0.0011
0.0041

0.9622

100 (47%)
44 (21%)
32 (15%)
23 (11%)
14 (7%)
14 (3.6)
N/A

N/A
N/A

43
30
8
6
6
14
52

(46%)
(32%)
(9%)
(6%)
(6%)
(3.6)
(85%)

19
12
26
39
62

(12%)
(8%)
(16%)
(25%)
(39%)

69
49
66
91
93
63
0.5
58
0.3
65
0.4
112

(19%)
(13%)
(18%)
(25%)
(25%)
(29.9)
(1.2)
(30.8)
(1.3)
(30.0)
(2.0)
(34%)

20
14
24
40
60
76
1.0
55
0.2
75
1.0
98

(13%)
(9%)
(15%)
(25%)
(38%)
(25.4)
(1.1)
(29.6)
(1.1)
(25.5)
(1.1)
(52%)

Case
N = 161

(13%)
(14%)
(26%)
(19%)
(28%)

8
6
9
15
23

(13%)
(10%)
(15%)
(25%)
(38%)

37
25
32
45
48
63
0.5
59
0.3
65
0.6
61

(20%)
(13%)
(17%)
(24%)
(26%)
(30.6)
(1.2)
(32.3)
(1.4)
(30.8)
(1.3)
(34%)

9
8
5
13
26
72
0.9
53
0.2
71
0.9
33

(15%)
(13%)
(8%)
(21%)
(43%)
(29.3)
(1.3)
(29.6)
(1.1)
(29.0)
(1.3)
(48%)

119 (57%)
28 (14%)
33 (16%)
17 (8%)
10 (5%)
14 (3.7)
N/A

67
44
28
15
7
14
107

(42%)
(27%)
(17%)
(9%)
(4%)
(3.3)
(80%)

11.9 (1.2)
N/A

11.6 (1.3)
1.7 (1.4)

0.9662

0.0252
0.0611

28
27
39
37
50

(15%)
(15%)
(22%)
(20%)
(28%)

11
6
17
24
39

(11%)
(6%)
(18%)
(25%)
(40%)

32
24
34
46
45
64
0.5
58
0.4
64
0.2
51

(18%)
(13%)
(19%)
(25%)
(25%)
(29.1)
(1.2)
(29.2)
(1.2)
(29.2)
(2.6)
(33%)

11
6
19
27
34
79
1.1
57
0.2
78
1.0
65

(11%)
(6%)
(20%)
(28%)
(35%)
(22.6)
(0.9)
(29.7)
(1.1)
(22.9)
(1.0)
(54%)

0.1181

0.0182
0.0182
0.1852
0.1852
0.1252
0.1252
0.0571

P

0.0041

0.2631
25
26
48
35
52

0.0311

<0.0012
<0.0012
0.2012
0.2012
<0.0012
<0.0012
<0.0011

0.6142

N/A
1.6 (1.2)

0.0101
(14%)
(14%)
(24%)
(20%)
(28%)

Control
N = 207

0.0821

N/A
1.7 (1.3)

53
53
87
72
102

P

0.1351

<0.0012
<0.0012
0.6562
0.6562
<0.0012
<0.0012
<0.0011

BMI, body mass index
1
Fishers exact test comparing MS cases to non-MS controls.
2
Two-sided Wilcoxon rank-sum with normal approximation and continuity correction comparing MS cases to non-MS controls.
3
Nearest the time of the first event, within 1 year.
4
Age at onset for cases, and age at enrollment for controls.
5
Overweight or obese if greater-than 85th percentile BMI for age.
6
Missing or invalid data for the following overall (girls): menarcheal/pubertal status at onset: 59 (27) cases; menstrual age: 78 (78) controls, 49
(49) cases; first available EDSS: 9 (7) cases; Tanner stage 1: 53 (26) controls, 96 (64) cases; Tanner stage 2: 52 (26) controls, 96 (64) cases; BMI
missing or Z> 4: 92 (57) controls, 65 (41) cases; Height for age missing or Z > 4: 89 (51) controls, 66 (42) cases; Weight for age missing or
Z>4: 59 (37) controls, 66 (41) cases.

(Fisher’s exact test P = 0.013). There was no such relationship among controls (Fisher’s exact P = 1.00).

Risk of MS: effect of BMI and pubertal age
BMI effect
We used a set of logistic regression models to estimate the
effect of both BMI and puberty on the risk of MS (Table 2).

Girls
In postmenarcheal girls, BMI z-score was associated
with risk of MS with an unadjusted odds ratio of 1.68
(CI: 1.21, 2.34, P = 0.002) and adjusted odds-ratio of
1.60 (CI: 1.12, 2.27, P = 0.009). In premenarcheal onset
girls, there was no significant effect of BMI on risk of
MS.
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Figure 1. (A and B) Boxplots of Body Mass Index (BMI) z-scores
calculated from height and weight for cases and controls. For MS
cases, measurements were taken at the clinic visit following first
symptoms, excluding cases seen more than 1 year after first
symptoms. Z-scores represent the number of standard deviations
above (+) or below (-) the average BMI adjusted for age. Boys (A) and
girls (B) are plotted separately. (C) Boxplots of menstrual age reported
by girls. Boxplots show the 25th and 75th percentiles (box), median
(center line), mean (X), max/min or 1.5 times the interquartile range
(vertical lines with caps), and observations beyond 1.5 times the
interquartile range (circles).

Boys
Models fit to pre and pubertal/postpubertal boys were
similar and limited by numbers. Therefore, we fit a model
to all boys (Table 2). According to that model, the odds
of developing MS were greater when BMI was higher
(adjusted OR 1.43, 95% CI: 1.08, 1.88).

Mediation and interaction of menarche and
the effect of BMI on the risk of MS:
Due to the correlation between BMI and age at menarche
among females, we used a method explained by VanderWeele24 to estimate the possible interacting and mediating influence of menarche on the effect of age-adjusted BMI
on the risk of MS in postmenarcheal females (Table S3).
This mediation and interaction model estimated the oddsratio of MS for overweight or obese females to be 2.18 (CI:
0.79, 3.57) compared to females with lower BMI, which is in
line with the odds-ratios for a continuous BMI predictor
obtained in our adjusted and unadjusted models (1.68 and
1.60). Neither interaction nor mediation components of
menarcheal age contributed significantly to the overall effect
of BMI on the risk of MS (Table S2).

Effect of BMI and puberty age on age at
first symptoms
Age at first symptoms in girls
In postmenarcheal-onset girls, race/ethnicity category
showed no significant effect on age at onset. Younger
menarcheal age showed a nonsignificant trend with
younger age at onset in univariable linear regression
(Slope coefficient: 0.3, 95% CI: 0.0, 0.6; P = 0.059).
Higher BMI z-score was associated with younger age at
first symptom onset in univariable linear regression
(Slope coefficient: 0.5, 95% CI: 0.9, 0.0; P = 0.031),
but was not significant in multivariable regression models
adjusted for menstrual age. This model may be limited
due to collinearity between predictors since BMI and
menarcheal age are highly correlated and sufficient BMI is
required in order to reach menarche (Table 3).
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Figure 2. Tanner stage for boys (A) and girls (B). Tanner stage was
documented at the first clinic visit following first symptoms, excluding
cases seen more than 1 year after first symptoms. (C) Menarchal
status for girls at the time of first symptoms. Girls with menarche at
the same age (in years) as first symptoms are counted as
postmenarche.

Mediation and interaction of menarche and the
effect of BMI on the age of first symptoms in
postmenarcheal girls with MS
Due to the relationship and between BMI and menarche,
we used a regression model detailed by VanderWeele24 to
estimate how menarcheal age interacts with, and mediates, the effect of age-adjusted BMI on age of onset for
postmenarcheal female MS patients. According to this
model, there was evidence that BMI influences age at
onset. Age of onset occurred 0.91 (95% CI: 0.14, 1.67,
P = 0.022) years earlier on average for overweight or
obese females versus those with a lower BMI (categorized
as being less than the 85th percentile according to BMI).
The strength of that effect differed by menarcheal age,
with younger menarche being associated with stronger
effects of BMI. Fixing menarcheal age at 10 resulted in an
estimated direct effect for BMI of 1.78 years earlier onset
(CI: 0.45, 3.10, P = 0.009); fixing menarcheal age at 11
resulted in an estimated 1.18 years earlier onset (CI: 0.31,
2.04, P = 0.008); a menarcheal age of 12 resulted in
0.58 years earlier onset (CI: 0.19, 1.34, P = 0.137); and
a menarcheal age 13 resulted in 0.02 years later onset (CI:
1.09, 1.14, P = 0.965).
Age at first symptoms in boys
In the pubertal/postpubertal boys, advanced sexual maturity (i.e., being more than one standard deviation in age
below the average enrolled control with the same Tanner
stage), showed a significant association with younger age
at onset in univariable and multivariable analysis. Boys
with advanced sexual maturity were 3.6 years younger at
MS onset compared to those that were closer-to, or above
the average age for their Tanner stage (P < 0.001).
Although BMI was itself not a predictor of age at onset,
89% (8/9) of the sexually advanced MS boys in the analysis were overweight or obese.

Discussion
We have observed distinct effects of obesity and sexual
maturity on risk of pediatric MS and age at MS onset.
Markers of sexual maturity, particularly in association
with increased BMI were associated with younger age at
onset in both boys and girls, while obesity alone was associated with increased risk of MS in both boys and girls.
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Table 2. Risk of MS: Logistic regression results modeling the odds of MS (cases) compared to Non-MS (controls). Pre and Postpubertal1 boys and
girls modeled separately. Odds-ratios with 95% confidence intervals (CI) are shown.

Model

Characteristic

Unadjusted
Odds-Ratio (95% CI)

P-value

Adjusted3
Odds-Ratio (95% CI)

P-value

Postmenarcheal Girls: (N = 181, 83 cases)

BMI-for-age z-score
Menarcheal Age
BMI-for-age z-score
BMI-for-age z-score
Advanced Maturity2

1.68
0.83
1.48
1.42
1.09

0.002
0.116
0.143
0.009
0.844

1.60
0.97
1.12
1.43
0.99

0.009
0.841
0.711
0.011
0.975

Premenarcheal Girls (N = 57, 19 cases)
All Boys
(N = 207, 59 cases)

(1.21, 2.34)
(0.65, 1.05)
(0.88, 2.51)
(1.09, 1.86)
(0.47, 2.54)

(1.12, 2.27)
(0.75, 1.26)
(0.61, 2.08)
(1.08, 1.88)
(0.41, 2.38)

BMI, body mass index
Postpubertal defined as postmenarche (females) or Tanner II ≥ 2 (males).
2
A boy has advanced maturity if his age is more than 1 standard deviation below the average age of controls with the same Tanner stage (pubic
hair). Boys in stage I are not advanced. Tanner stage must be measured within 1 year of first symptoms for cases.
3
Adjusted for factors shown and race/ethnicity.
4
Bolded are statistically significant. p<0.05
1

Table 3. Linear regression analysis results for age at symptom onset. Pre and postpubertal1 boys and girls modeled separately. Regression
coefficients with 95% confidence intervals (CI) are shown.

Model

Characteristic

Postmenarcheal onset Girls: (N = 83)

Intercept4
BMI-for-age z-score
Menarcheal Age
Black NH
Other NH
Hispanic-Latino
White NH
Intercept4
BMI-for-age z-score
Black NH
Other NH
Hispanic-Latino
White NH
Intercept4
BMI-for-age z-score
Advanced Sexual Maturity2
Black NH
Other NH
Hispanic-Latino
White NH
Intercept4
BMI-for-age z-score
Black NH
Other NH
Hispanic-Latino
White NH

Premenarcheal onset Girls (N = 19)

Pubertal/Postpubertal Boys (N = 50)

Prepubertal Boys (N = 9)

Univariable Linear
Regression
Coefficient (95% CI)

P-value3

0.5 ( 0.9, 0.0)
0.3 ( 0.0, 0.6)
0.4 ( 1.4, 0.7)
1.3 ( 2.6, 0.0)
0.7 ( 1.6, 0.2)
Reference

0.031
0.059
0.181

1.3 ( 3.4, 0.8)
3.4 ( 7.6, 0.8)
4.8 ( 8.6, 1.1)
6.1 ( 9.6, 2.5)
Reference

0.221
0.012

0.1 ( 0.6, 0.4)
2.8 ( 4.2, 1.4)
0.0 ( 3.2, 3.2)
0.6 ( 3.8, 2.6)
0.8 ( 2.1, 0.5)
Reference

0.610
<0.001
0.689

1.5 ( 3.1, 0.0)
1.6 ( 9.6, 6.4)
2.3 ( 12.4, 7.9)
1.2 ( 6.0, 8.3)
Reference

0.055
0.758

Multivariable Linear
Regression
Coefficient (95% CI)
13.0 (8.9, 17.0)
0.4 ( 0.8, 0.0)
0.3 ( 0.1, 0.6)
0.2 ( 1.3, 0.8)
1.6 ( 2.9, 0.4)
0.5 ( 1.3, 0.4)
Reference
12.0 (9.6, 14.4)
0.0 ( 2.0, 2.0)
3.4 ( 7.8, 1.0)
4.8 ( 8.8, 0.9)
6.1 ( 10.3, 1.9)
Reference
15.4 (14.7, 16.2)
0.2 ( 0.2, 0.7)
3.6 ( 5.2, 1.9)
0.4 ( 3.2, 2.4)
2.4 ( 0.8, 5.5)
0.3 ( 1.5, 1.0)
Reference
9.5 (4.0, 15.1)
1.6 ( 3.9, 0.6)
0.0 ( 7.2, 7.2)
3.1 ( 11.9, 5.6)
0.9 ( 5.2, 7.0)
Reference

P-value3
<0.001
0.072
0.096
0.090

<0.001
0.993
0.031

<0.001
0.329
<0.001
0.374

0.009
0.117
0.674

BMI, body mass index.
1
Postpubertal defined as postmenarche (females) or Tanner stage (pubic hair) ≥ 2 (males).
2
A boy has advanced maturity if his age is more than 1 standard deviation below the average age of controls with the same Tanner stage (pubic
hair). Boys in stage I are not advanced. Tanner stage must be measured within 1 year of first symptoms for cases.
3
P-values from Type III tests.
4
Univariable regression coefficients are from separate models, each with their own intercept term.
5
Bolded are statistically significant, p<0.05
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Using markers of sexual development, we demonstrate
that prepubertal onset of MS is rare, with only 11% of
girls and 15% of boys classified as Tanner stage I at onset.
Only 20% of girls were premenarcheal at MS onset. These
results suggest that the onset of puberty may be a key
turning point for the onset of MS. A complex relationship
between menarcheal age and obesity on age at onset of
MS appears to exist. Our results suggest that when
menarche occurs at a younger than average age, increased
BMI has an effect on age at onset. Menarcheal age itself
had a marginal effect on age at onset. This interaction
may be used to inform further studies assessing sex hormone and adipokine analysis on early pathogenetic mechanisms in MS.
Earlier age at pubarche, which requires a testosterone
surge by the adrenals and/or testes, was associated with
earlier age at MS onset in boys. Interestingly, the more
sexually mature boys were also more obese. In males,
higher BMI is typically associated with greater peripheral
conversion of adrenal and gonadal androgens to estrogens
(estrone and estradiol, respectively) in adipose tissue, consistent with a role of circulating estrogens in MS pathogenesis.26 Interestingly, in men with MS, there is evidence
of decreased prenatal androgen exposure,29 and this association, with respect to our observations, requires further
study in boys with MS.
Several studies have shown that obesity in the adolescent
years, but not the adult years, is a risk factor for MS.7–11
This study further emphasizes this trend and confirms a
role of obesity in development of pediatric-onset MS. In
contrast to another pediatric study which demonstrated an
effect only in girls,12 we found obesity to be a risk factor in
both boys and postmenarcheal-onset girls. Obesity is associated with a change in adipokine profiles including an
increase in leptin which plays a proinflammatory role, and
lowered ghrelin which is anti-inflammatory. These adipokines play varied role in thymic maturation, T-cell proliferation, development of memory cells and cytokine
production,17,28–31 all mechanisms which are purported to
play a role in pediatric-onset MS.32–35
The limitations of this study are that BMI was measured after disease onset, and arguably could be the result
of increased disability. However, mean EDSS in our cases
was low, and only patients with body measurements
within 1 year of disease onset were included. Steroid use
could contribute to differences in measures; however,
these are early MS cases, with relatively short exposures
to these agents. The relatively lower number of prepubertal subjects could significantly limit power to detect associations in this group, and therefore current results
should be replicated in a larger datasets including larger
numbers of prepubertal subjects. Another significant limitation is missing data, particularly Tanner staging in 32 of

Puberty and Obesity effects on risk and age at pediatric MS

the MS boys. This in particular, could influence the risk
of MS analysis, where Tanner staging and sexual maturity
was not found to play a role in our current analysis.
Strengths of our study include a large cohort of children with MS including boys and girls with representation from centers across the United States. The
examination of BMI along with measures of sexual maturation allows us to examine the interplay of these factors,
which may affect MS immunopathogenesis through differential mechanisms.
In summary, our study supports the growing data that
adolescent obesity is a risk factor for MS, and confirms a
role in pediatric-onset MS in both boys and girls. This
finding is of significant concern given the growing rates
of pediatric obesity worldwide,36 and may contribute to
the observations of an increasing female gender ratio in
MS over the past five decades.37 Our study highlights an
effect of sexual maturity and the pubertal transition on
the age of MS onset, particularly in association with obesity. Further studies are required to elucidate the
immunopathogenetic mechanisms mediated by these hormonal factors in the early stages of MS.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Figure S1. Scatterplots of age-adjusted BMI z-score for
MS cases (A) and controls (B). For MS cases, height and
weight measurements were taken at the clinic visit
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following first symptoms, excluding cases seen more than
1 year after first symptoms. For controls, BMI was taken
at the time of enrollment.
Figure S2. Scatterplots and boxplots of age at first symptoms (y-axis) and factors (x-axes) included in statistical
models to determine association between obesity (BMI zscores), puberty (menstrual age for girls, and advanced
maturity for boys), and race/ethnicity. Post and prepubertal girls and boys were modeled separately.
Table S1. Comparison of MS cases to the US population
estimates from NHANES dataset.
Table S2. Mediation and Interaction of Menarcheal Age
and the Effect of BMI on the Risk of MS.
Table S3. Mediation and Interaction of Menarcheal Age
and the Effect of BMI on Age at Onset among pubertal/
postpubertal female MS patients.
Table S4. Comparison of demographic criteria in subjects
enrolled in overarching E+G study, and those eligible for
this analysis.
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